---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-087289"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:01:39.550384+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma Q3 2023 revenue down 62% to $16K; net loss improves 11% to $3.37M

## Summary
- Q3 2023 revenue $15,884 vs $42,269 in Q3 2022; cash increased to $500K from $85K at year-end 2022.
- Net loss narrowed to $3.37M from $3.78M; operating expenses fell 43% to $2.14M.
- MDD drug ABV-1504 completes Phase II; licensing deal with Xinnovation worth up to $20M for China rights.
- Signed global licensing agreement with AIBL for CNS drugs valued at $667M; ABVC and BioLite to receive 23M AIBL shares at $10/share plus milestones.
- Regained Nasdaq minimum bid price compliance; shareholders' equity at $9.1M.

## SEC filing metadata
- accession: 0001213900-23-087289
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023087289/0001213900-23-087289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023087289/ea188352-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-087289
- JSON: https://secwatch.observer/filing/0001213900-23-087289.json
- Plain text: https://secwatch.observer/filing/0001213900-23-087289.txt

## Key facts
- Earnings Releases
  ABVC BIOPHARMA, INC. reported third quarter ended September 30, 2023 results: revenue $15,884, net income The net loss was $3,368,080.
  - Period: third quarter ended September 30, 2023
  - Revenue: $15,884
  - Net income: The net loss was $3,368,080
  - Result: reported results
  source text: achieved a total shareholders’ equity of $9.10M and therefore believes it has regained the compliance with NASDAQ’s shareholders’ equity requirement. ● Revenues . We generated $15,884 and $42,269 in revenues for the three months ended September 30, 2023 and 2022, respectively. The decrease in revenues was due to completion of ongoing projects and awaiting new
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023087289/0001213900-23-087289-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.